Stellar Biotechnologies reported a 7 percent drop in revenue for the third quarter, and net losses stayed flat at $5.03 million. Shares shot up after the announcement Nov. 30 and continued to climb in after-hours trading to $1.15, up more than 12 percent. The Port Hueneme company, which manufactures keyhole limpet hemocyanin proteins for immunotherapies,…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
